Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Autolus Therapeutics plc AUTL
$1.93
+$0.08 (4.05%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
322784890.00000000
-
week52high
3.79
-
week52low
1.60
-
Revenue
6194000
-
P/E TTM
-1
-
Beta
1.57597000
-
EPS
-1.65000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:30
Описание компании
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 05 авг 2022 г. |
| Truist Securities | Buy | Buy | 14 июн 2022 г. |
| Needham | Buy | Buy | 06 мая 2021 г. |
| Redburn | Neutral | Buy | 10 мар 2021 г. |
| JP Morgan | Neutral | Overweight | 29 янв 2021 г. |
| Needham | Buy | Buy | 09 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Autolus Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
GlobeNewsWire
20 апр 2023 г. в 07:00
LONDON, April 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2023 financial results and operational highlights before open of U.S. markets on Thursday, May 4, 2023.
Autolus Therapeutics (AUTL) Q4 2022 Earnings Call Transcript
Seeking Alpha
07 мар 2023 г. в 14:04
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Julia Wilson - Consilium Strategic Advisors Conference Call Participants Gil Blum - Needham & Co. Mara Goldstein - Mizuho Group Matthew Phipps - William Blair Kelly Shi - Jefferies James Shin - Wells Fargo Sebastiaan van der Schoot - Van Lanschot Kempen Karina Rabayeva - Truist Securities Operator Ladies and gentlemen, welcome to the Autolus Therapeutics full year 2022 financial results conference call and fourth quarter operational progress. As a reminder, this conference is being recorded.
Autolus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 7, 2023
GlobeNewsWire
15 февр 2023 г. в 07:00
LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2022 financial results and operational highlights before open of U.S. markets on Tuesday, March 7, 2023.
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
GlobeNewsWire
12 дек 2022 г. в 10:00
LONDON, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three posters with updates from three Phase 1 clinical trials to be presented at the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2022.
Why Autolus Therapeutics Stock Is Crashing Today
The Motley Fool
09 дек 2022 г. в 11:31
The biopharmaceutical company announced the pricing of a secondary stock offering.